Ergonovine is named as an intervention in 2 current clinical trials in our Canada and Egypt registers. 2 are recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is Samuel Lunenfeld Research Institute, Mount Sinai Hospital (1). The most-studied condition is Postpartum Hemorrhage.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
NCT06285409 · ClinicalTrials.gov ↗ · Postpartum Hemorrhage
|
Not applicable | Recruiting | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Canada |
|
Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy
NCT07390864 · ClinicalTrials.gov ↗ · Myoma;Uterus
|
Not applicable | Recruiting | Cairo University | Egypt |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Samuel Lunenfeld Research Institute, Mount Sinai Hospital | 1 |
| Cairo University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Canada and Egypt registers name Ergonovine as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in Canada and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital (1) and Cairo University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ergonovine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ergonovine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ergonovine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.